Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz is a peptide-PEG based ADC linker intermediate incorporating Gly-Gly-Phe-Gly sequence and PEG4 spacer, designed for enzyme-cleavable payload release in antibody-drug conjugates. Keywords: ADC linker, peptide linker, PEG spacer, enzyme-cleavable, controlled release.
Structure of 2914227-56-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz, a versatile biochemical reagent, finds wide applications in peptide synthesis and drug delivery systems. Here are four key applications:
Peptide Synthesis: Playing a pivotal role in solid-phase peptide synthesis, Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz aids in crafting intricate peptide chains. The Fmoc group acts as a protective shield for the amino terminus, ensuring seamless synthesis. This reagent facilitates the meticulous assembly of peptides, guaranteeing high purity and yield in the final products.
Drug Delivery Systems: Delving into the realm of drug delivery systems, this reagent features prominently in optimizing the solubility and stability of therapeutic agents. The PEG spacer injects hydrophilicity, enhancing the bioavailability of hydrophobic drugs. Featuring a GGFG sequence as a cleavable linker, it artfully unveils the active drug under specific physiological conditions, maximizing therapeutic potential.
Protein Conjugation: In the protein conjugation, Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz steps in to amplify the functionality and therapeutic efficacy of proteins. The PEG spacer acts as a shield against immunogenicity and prolongs the half-life of therapeutic proteins. Conjugating with this reagent promises enhanced pharmacokinetic and pharmacodynamic profiles.
Bioconjugate Chemistry: Diving into bioconjugate chemistry, this reagent offers a gateway to meld various biomolecules like antibodies, enzymes, and nucleic acids with targeting moieties or functional groups. PEGylation, a key feature, mitigates steric hindrance and bolsters overall stability. These bioconjugates facilitate targeted drug delivery and molecular imaging.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00582 | Fmoc-PEG4-NHS ester | 1314378-14-7 | |
BADC-01044 | Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB | 2055042-69-6 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.